(2025). In vivo Therapeutic Inhibition of the Tp53-Induced Glycolysis and Apoptosis Regulator (TIGAR) by Intravenous Administration of an Anti-Oncological siRNA-Biopolymer, TI6752 (Tituxistatin), in a Preclinical Xenograft Model of Colorectal Cancer. Journal of Experimental Pharmacology.
Successfully copied to clipboard
Copying to clipboard failed
Chicago Style (17th ed.) Citation
"In Vivo Therapeutic Inhibition of the Tp53-Induced Glycolysis and Apoptosis Regulator (TIGAR) by Intravenous Administration of an Anti-Oncological SiRNA-Biopolymer, TI6752 (Tituxistatin), in a Preclinical Xenograft Model of Colorectal Cancer."
Journal of Experimental Pharmacology 2025.
Successfully copied to clipboard
Copying to clipboard failed
MLA (9th ed.) Citation
"In Vivo Therapeutic Inhibition of the Tp53-Induced Glycolysis and Apoptosis Regulator (TIGAR) by Intravenous Administration of an Anti-Oncological SiRNA-Biopolymer, TI6752 (Tituxistatin), in a Preclinical Xenograft Model of Colorectal Cancer."
Journal of Experimental Pharmacology, 2025.
Successfully copied to clipboard
Copying to clipboard failed
Warning: These citations may not always be 100% accurate.